SYFOVRE®

Hold Company

APELLIS PHARMS

Learn More

Dosage and Administration

SOLUTION;INTRAVITREAL

Specification

15MG/0.1ML (15MG/0.1ML)

Indication

SYFOVRE® is used in the treatment of age-related macular degeneration (AMD) secondary geographic atrophy (GA).

Use

Instructions for Use

API

PEGCETACOPLAN

API Structure

We Supply

PEGCETACOPLAN

Note:

null

null

Note:

null

null

Note:

null

Drug Patent

Patent No	Expiration Date
10035822	2033/11/15
10125171	2033/8/2
10875893	2033/11/15
11292815	2033/11/15
11661441	2033/1/13
7888323	2027/12/4
7989589	2027/12/4
8168584	2027/4/7
9056076	2026/10/25
9169307	2027/11/18

API Patent

Patent No	Expiration Date
7888323	2027/12/4
7989589	2027/12/4
9169307	2027/11/18

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.